Sigma Planning Corp’s Neurocrine Biosciences NBIX Stock Holding History

Sigma Planning Corp’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69M	Buy	+10,008	New	+$1.48M	0.04%	414
2024 Q4	–	Sell	-2,000	Closed	-$230K	–	1226
2024 Q3	$230K	Buy	+2,000	New	+$274K	0.01%	1074
2024 Q2	–	Sell	-10,100	Closed	-$1.39M	–	1237
2024 Q1	$1.39M	Buy	+10,100	New	+$1.38M	0.04%	403
2020 Q3	–	Sell	-3,795	Closed	-$463K	–	1131
2020 Q2	$463K	Buy	+3,795	New	+$419K	0.02%	622
2018 Q4	–	Sell	-2,370	Closed	-$291K	–	929
2018 Q3	$291K	Hold	2,370	–	–	0.02%	708
2018 Q2	$233K	Sell	2,370 -1,020	-30%	-$91.3K	0.02%	764
2018 Q1	$281K	Buy	3,390 +290	+9%	+$24.5K	0.02%	633
2017 Q4	$241K	Buy	+3,100	New	+$211K	0.02%	695

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sigma Planning Corp's NBIX Position: Q2 2026 in Review

Sigma Planning Corp opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 10,008 shares worth $1.69M. The stake represents 0.04% of the portfolio and ranks #414 among its holdings. This is a return to the name: Sigma Planning Corp previously reported a position in NBIX as recently as Q3 2024.

Sigma Planning Corp first reported a position in NBIX in Q4 2017 and has held it in 8 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Sigma Planning Corp held 10,008 shares of Neurocrine Biosciences worth $1.69M as of Q2 2026.
Neurocrine Biosciences was a new Sigma Planning Corp position in Q2 2026.
Neurocrine Biosciences made up 0.04% of Sigma Planning Corp's portfolio in Q2 2026, its #414 holding.
Sigma Planning Corp first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 8 quarters since.
779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.